X

CINNARON 25 TABLET 25mg

Product Information

Registration Status: Active

SIN02924P

CINNARON 25 TABLET 25mg is approved to be sold in Singapore with effective from 1989-05-22. It is marketed by GOLDPLUS UNIVERSAL PTE LTD, with the registration number of SIN02924P.

This product contains Cinnarizine 25mg in the form of TABLET. It is approved for ORAL use.

This product is manufactured by REMEDICA LTD in CYPRUS.

It is a Pharmacy Only Medicine that can be obtained from a pharmacist at a retail pharmacy.

Product Reference
Loading...


Description

Cinnarizine is an anti-histaminic drug which is mainly used for the control of vomiting due to motion sickness. Cinnarizine was first synthesized by Janssen Pharmaceutica in 1955. It acts by interfering with the signal transmission between vestibular apparatus of the inner ear and the vomiting centre of the hypothalamus. The disparity of signal processing between inner ear motion receptors and the visual senses is abolished, so that the confusion of brain whether the individual is moving or standing is reduced. Vomiting in motion sickness is actually a physiological compensatory mechanism of the brain to keep the individual from moving so that it can adjust to the signal perception. Cinnarizine could be also viewed as a nootropic drug because of its vasorelaxating abilities (due to calcium channel blockage), which happen mostly in brain. It is also effectively combined with other nootropics, primarily piracetam; in such combination each drug potentiate the other in boosting brain oxygen supply.

Indication

For the treatment of vertigo/meniere's disease, nausea and vomiting, motion sickness and also useful for vestibular symptoms of other origins.

Mechanism of Action

Cinnarizine inhibits contractions of vascular smooth muscle cells by blocking L-type and T-type voltage gated calcium channels. Cinnarizine has also been implicated in binding to dopamine D2 receptors, histamine H1 receptors, and muscarinic acetylcholine receptors.

Active Ingredient/Synonyms

1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine | 1-Benzhydryl-4-cinnamylpiperazin | 1-Cinnamyl-4-(diphenylmethyl)piperazine | Cinarizina | Cinnarizine | Cinnarizinum | Cinnarizine |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank

Pharmfair.com uses cookies to improve your browsing experience. We'll assume you're ok with this, but you can opt-out if you wish. Peace!